Clinical strategy for the development of angiogenesis inhibitors

Oncologist

Volumn 5, Issue SUPPL. 1, 2000, Pages 51-54

  Carter, Stephen K ^a,b  

^a SUGEN INC   (United States)

^b NONE   (United States)

Author keywords

Angiogenesis; Clinical study design; Cytostatic agents; Cytotoxic agents

Indexed keywords

3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANGIOGENESIS INHIBITOR; CYTOTOXIC AGENT; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LUNG NON SMALL CELL CANCER; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0033994955     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.5-suppl_1-51     Document Type: Conference Paper

References (0)